The Role of Regorafenib in Hepatocellular Carcinoma.
作者信息
Frenette Catherine T
机构信息
Medical Director of Liver Transplantation Director, Hepatocellular Carcinoma Program Scripps Center for Organ Transplantation Scripps Clinic/Green Hospital La Jolla, California.
出版信息
Gastroenterol Hepatol (N Y). 2017 Feb;13(2):122-124.
Abstract
摘要
相似文献
1
The Role of Regorafenib in Hepatocellular Carcinoma.
Gastroenterol Hepatol (N Y). 2017 Feb;13(2):122-124.
2
Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
Oncologist. 2018 Apr;23(4):496-500. doi: 10.1634/theoncologist.2017-0422. Epub 2018 Jan 31.
3
Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment.
Cancer Chemother Pharmacol. 2017 Nov;80(5):945-954. doi: 10.1007/s00280-017-3431-5. Epub 2017 Sep 20.
4
Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.
Cancer Lett. 2019 Jul 1;453:74-83. doi: 10.1016/j.canlet.2019.03.037. Epub 2019 Mar 27.
5
Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
Eur J Pharm Sci. 2017 Nov 15;109S:S149-S153. doi: 10.1016/j.ejps.2017.05.050. Epub 2017 May 23.
6
Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
Cancer. 2017 Oct 1;123(19):3725-3731. doi: 10.1002/cncr.30863. Epub 2017 Jun 29.
7
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.
8
Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice.
Biosci Rep. 2018 May 8;38(3). doi: 10.1042/BSR20171264. Print 2018 Jun 29.
9
Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
Dig Dis. 2017;35(6):611-617. doi: 10.1159/000480257. Epub 2017 Oct 17.
10
Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity.
Intern Med. 2019 Oct 1;58(19):2803-2808. doi: 10.2169/internalmedicine.2812-19. Epub 2019 Jun 27.
引用本文的文献
1
A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma.
Curr Oncol. 2022 Sep 8;29(9):6445-6462. doi: 10.3390/curroncol29090507.
2
Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma.
Cancers (Basel). 2021 May 1;13(9):2182. doi: 10.3390/cancers13092182.
3
New 3-Aryl-2-(2-thienyl)acrylonitriles with High Activity Against Hepatoma Cells.
Int J Mol Sci. 2021 Feb 24;22(5):2243. doi: 10.3390/ijms22052243.
4
Rotundic Acid Induces DNA Damage and Cell Death in Hepatocellular Carcinoma Through AKT/mTOR and MAPK Pathways.
Front Oncol. 2019 Jun 26;9:545. doi: 10.3389/fonc.2019.00545. eCollection 2019.
5
Hepatocellular carcinoma treatment: hurdles, advances and prospects.
Hepat Oncol. 2018 Sep 28;5(2):HEP08. doi: 10.2217/hep-2018-0002. eCollection 2018 Apr.
6
Role of microRNAs in the development of hepatocellular carcinoma and drug resistance.
Front Biosci (Landmark Ed). 2019 Jan 1;24(2):382-391. doi: 10.2741/4724.
本文引用的文献
1
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6.
2
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22.
3
Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.
J Support Oncol. 2011 Jan-Feb;9(1):13-23. doi: 10.1016/j.suponc.2010.12.007.
4
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
Int J Cancer. 2011 Jul 1;129(1):245-55. doi: 10.1002/ijc.25864. Epub 2011 Apr 22.
5
Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
Zotero 插件